

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.*



## **Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

### **EXTENSION OF LONG STOP DATE IN RELATION TO THE PLACING OF NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement of Link-Asia International MedTech Group Limited (the “**Company**”) dated 4 September 2023 in relation to the Placing of new Shares under General Mandate (the “**Announcement**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, the completion of the Placing is conditional upon the fulfillment of the condition set out in the section headed “Conditions of the Placing” of the Announcement on or before 18 September 2023 (or such later date as the Company and the Placing Agent may agree in writing) (the “**Long Stop Date**”).

As additional time is required for the Company to fulfill the conditions precedent set out in the Placing Agreement, on 18 September 2023 (after trading hours), the Company and the Placing Agent entered into a supplemental agreement to the Placing Agreement after arm’s length negotiations (the “**Supplemental Placing Agreement**”), pursuant to which the Company and the Placing Agent agreed to extend the Long Stop Date of the Placing Agreement from 18 September 2023 to 9 October 2023 (or such later date as the Company and the Placing Agent may agree in writing).

The Directors consider that the terms of the Supplemental Placing Agreement are on normal commercial terms and fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Save and except for the change disclosed above, all other terms and conditions of the Placing Agreement remain unchanged and continue to remain in full force and effect.

**Since the Completion is subject to the satisfaction of the conditions precedent as set out in the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.**

On behalf of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and executive Director*

Hong Kong, 18 September 2023

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Liu Zhiwei, Ms. Lin Xiaoshan and Ms. Bian Sulan as executive Directors; Mr. Li Huiwu, Mr. Wu Chi King and Mr. Chak Chi Shing as independent non-executive Directors.*